SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2185802

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2185802

Geriatric Medicines Market Insights, Competitive Landscape, and Market Forecast - 2033

PUBLISHED:
PAGES: 287 Pages
DELIVERY TIME: 2-5 business days
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 7295
Printable PDF & Excel (Enterprise License above 5 users)
USD 8495

Add to Cart

Introduction

Geriatric medicines address the conditions that become more common with age, from heart disease and diabetes to neurological, musculoskeletal and eye disorders. Older patients often live with several long-term illnesses at once, which means they take multiple medicines for many years and need products that are safe, easy to swallow and simple to manage. In 2026, the market is valued at US$412 Bn and is projected to reach US$538 Bn by 2033, registering a CAGR of 3.90%. This steady expansion is driven mainly by demographics rather than by sharp price increases, as the number of people above sixty-five continues to climb in both advanced and middle-income countries. At the same time, payers are pressing hard on prices through reference pricing, tenders and formal value assessments. The result is a market where volume grows reliably while value growth is carefully managed, rewarding companies that combine affordable access with formulations and delivery formats designed around the practical needs of older adults and their carers.

Market Insights

The market is segmented by therapeutic area, product class, formulation and delivery format, and distribution channel. Therapeutic areas include cardiovascular, central nervous system, musculoskeletal, oncology, diabetes and metabolic, respiratory, urological and ophthalmic medicines, reflecting the wide range of chronic conditions seen in later life. Product classes span generic small molecules, branded small molecules, biologics and biosimilars, with biosimilars playing a growing role in widening access to costly biologic therapies. Formulation choices go beyond conventional oral solids to include orodispersible tablets, liquids and suspensions, transdermal patches, prefilled devices and fixed-dose combinations, all of which help patients who struggle with swallowing, dexterity or complex dosing schedules. Distribution runs through retail pharmacies, hospital pharmacies, long-term care pharmacies and online pharmacies. Recent policy moves are shaping pricing and access, including the enactment of the US Inflation Reduction Act, a proposed revision of EU pharmaceutical legislation, the first negotiated Medicare Part D maximum fair prices and a new annual out-of-pocket cap for Part D enrollees.

Drivers

The leading growth force is the rising number of people above sixty-five who live with multiple long-term conditions, a driver rated high impact. Each additional chronic diagnosis tends to add another long-running prescription, so population ageing translates directly into sustained medicine volumes across cardiovascular, metabolic, neurological and other therapy areas. A second, medium-impact driver is the entry of biosimilars, which is widening payer access to biologic treatments that were previously limited by cost. As more biosimilars launch, older patients gain earlier access to therapies for conditions such as inflammatory and bone disorders. These drivers face firm restraints. Reference pricing, tendering and health technology assessment cap value growth, a high-impact pressure that keeps revenue rising more slowly than volume. Deprescribing policies, combined with thin clinical trial evidence in older patients, form a medium-impact restraint, since prescribers are encouraged to reduce unnecessary medicines and may hesitate to start treatments that lack data from elderly populations, limiting uptake of some newer products.

Business Opportunity

Age-appropriate formulations and prefilled devices offer a differentiated revenue pool. Many older patients have difficulty swallowing large tablets, handling small pills or following complicated dosing regimens. Orodispersible tablets, liquids, transdermal patches, fixed-dose combinations and prefilled devices can make treatment easier and improve adherence, which gives manufacturers a way to stand apart from standard generics and defend value even under strong price pressure. Carers and long-term care facilities also benefit from simpler administration, which strengthens the case for these products with pharmacies and payers.

The second opportunity lies in rapidly ageing middle-income health systems. As these countries see their older populations expand, governments and insurers are extending reimbursement to treatments for chronic disease, creating new demand that did not exist at scale before. Companies that can supply affordable, quality-assured medicines, work with local distribution partners and adapt formulations to regional needs are well placed to build lasting positions in these fast-changing healthcare systems over the forecast period.

Region Analysis

North America leads the market with a 36% share in 2026, supported by a large older population, high per-capita medicine spending and broad insurance coverage, even as negotiated pricing reshapes revenue for certain products. Europe holds 29%, where ageing demographics are pronounced but reference pricing, tendering and health technology assessment keep a tight lid on value growth. Asia Pacific accounts for 25% and is the fastest-growing region, expanding at 5.6% CAGR, as rapidly ageing societies and widening reimbursement lift demand for chronic disease treatments. Latin America represents 6% of the market, with growth linked to expanding public health coverage, generic uptake and a gradually older population. The Middle East and Africa holds 4%, where improving healthcare infrastructure and rising life expectancy are building demand for long-term therapies. Across all regions, the interplay between demographic momentum and payer cost control will decide how quickly volume gains turn into revenue, making pricing strategy and formulation design central to success.

Key Players

  • Pfizer Inc.
  • Novartis AG
  • Sanofi
  • GSK plc
  • AstraZeneca plc
  • Bayer AG
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim International GmbH

Segmentation

By Therapeutic Area:

  • Cardiovascular
  • Central Nervous System
  • Musculoskeletal
  • Oncology
  • Diabetes and Metabolic
  • Respiratory
  • Urological
  • Ophthalmic

By Product Class:

  • Generic Small Molecule
  • Branded Small Molecule
  • Biologic
  • Biosimilar

By Formulation and Delivery Format:

  • Conventional Oral Solid
  • Orodispersible Tablet
  • Liquid and Suspension
  • Transdermal Patch
  • Prefilled Device
  • Fixed-Dose Combination

By Distribution Channel:

  • Retail Pharmacy
  • Hospital Pharmacy
  • Long-Term Care Pharmacy
  • Online Pharmacy

By Geographic Coverage:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Geriatric Medicines Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Geriatric Medicines Market Outlook, 2020-2033

  • 3.1. Global Geriatric Medicines Market Outlook, by Therapeutic Area, Value (US$ Bn), 2020-2033
    • 3.1.1. Cardiovascular
    • 3.1.2. Central Nervous System
    • 3.1.3. Musculoskeletal
    • 3.1.4. Oncology
    • 3.1.5. Diabetes and Metabolic
    • 3.1.6. Respiratory
    • 3.1.7. Urological
    • 3.1.8. Ophthalmic
  • 3.2. Global Geriatric Medicines Market Outlook, by Product Class, Value (US$ Bn), 2020-2033
    • 3.2.1. Generic Small Molecule
    • 3.2.2. Branded Small Molecule
    • 3.2.3. Biologic
    • 3.2.4. Biosimilar
  • 3.3. Global Geriatric Medicines Market Outlook, by Formulation and Delivery Format, Value (US$ Bn), 2020-2033
    • 3.3.1. Conventional Oral Solid
    • 3.3.2. Orodispersible Tablet
    • 3.3.3. Liquid and Suspension
    • 3.3.4. Transdermal Patch
    • 3.3.5. Prefilled Device
    • 3.3.6. Fixed-Dose Combination
  • 3.4. Global Geriatric Medicines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 3.4.1. Retail Pharmacy
    • 3.4.2. Hospital Pharmacy
    • 3.4.3. Long-Term Care Pharmacy
    • 3.4.4. Online Pharmacy
  • 3.5. Global Geriatric Medicines Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.5.1. North America
    • 3.5.2. Europe
    • 3.5.3. Asia Pacific
    • 3.5.4. Latin America
    • 3.5.5. Middle East & Africa

4. North America Geriatric Medicines Market Outlook, 2020-2033

  • 4.1. North America Geriatric Medicines Market Outlook, by Therapeutic Area, Value (US$ Bn), 2020-2033
    • 4.1.1. Cardiovascular
    • 4.1.2. Central Nervous System
    • 4.1.3. Musculoskeletal
    • 4.1.4. Oncology
    • 4.1.5. Diabetes and Metabolic
    • 4.1.6. Respiratory
    • 4.1.7. Urological
    • 4.1.8. Ophthalmic
  • 4.2. North America Geriatric Medicines Market Outlook, by Product Class, Value (US$ Bn), 2020-2033
    • 4.2.1. Generic Small Molecule
    • 4.2.2. Branded Small Molecule
    • 4.2.3. Biologic
    • 4.2.4. Biosimilar
  • 4.3. North America Geriatric Medicines Market Outlook, by Formulation and Delivery Format, Value (US$ Bn), 2020-2033
    • 4.3.1. Conventional Oral Solid
    • 4.3.2. Orodispersible Tablet
    • 4.3.3. Liquid and Suspension
    • 4.3.4. Transdermal Patch
    • 4.3.5. Prefilled Device
    • 4.3.6. Fixed-Dose Combination
  • 4.4. North America Geriatric Medicines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 4.4.1. Retail Pharmacy
    • 4.4.2. Hospital Pharmacy
    • 4.4.3. Long-Term Care Pharmacy
    • 4.4.4. Online Pharmacy
  • 4.5. North America Geriatric Medicines Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.5.1. U.S. Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 4.5.2. U.S. Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 4.5.3. U.S. Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 4.5.4. U.S. Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
    • 4.5.5. Canada Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 4.5.6. Canada Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 4.5.7. Canada Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 4.5.8. Canada Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
  • 4.6. BPS Analysis/Market Attractiveness Analysis

5. Europe Geriatric Medicines Market Outlook, 2020-2033

  • 5.1. Europe Geriatric Medicines Market Outlook, by Therapeutic Area, Value (US$ Bn), 2020-2033
    • 5.1.1. Cardiovascular
    • 5.1.2. Central Nervous System
    • 5.1.3. Musculoskeletal
    • 5.1.4. Oncology
    • 5.1.5. Diabetes and Metabolic
    • 5.1.6. Respiratory
    • 5.1.7. Urological
    • 5.1.8. Ophthalmic
  • 5.2. Europe Geriatric Medicines Market Outlook, by Product Class, Value (US$ Bn), 2020-2033
    • 5.2.1. Generic Small Molecule
    • 5.2.2. Branded Small Molecule
    • 5.2.3. Biologic
    • 5.2.4. Biosimilar
  • 5.3. Europe Geriatric Medicines Market Outlook, by Formulation and Delivery Format, Value (US$ Bn), 2020-2033
    • 5.3.1. Conventional Oral Solid
    • 5.3.2. Orodispersible Tablet
    • 5.3.3. Liquid and Suspension
    • 5.3.4. Transdermal Patch
    • 5.3.5. Prefilled Device
    • 5.3.6. Fixed-Dose Combination
  • 5.4. Europe Geriatric Medicines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 5.4.1. Retail Pharmacy
    • 5.4.2. Hospital Pharmacy
    • 5.4.3. Long-Term Care Pharmacy
    • 5.4.4. Online Pharmacy
  • 5.5. Europe Geriatric Medicines Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.5.1. Germany Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 5.5.2. Germany Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 5.5.3. Germany Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 5.5.4. Germany Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
    • 5.5.5. Italy Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 5.5.6. Italy Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 5.5.7. Italy Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 5.5.8. Italy Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
    • 5.5.9. France Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 5.5.10. France Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 5.5.11. France Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 5.5.12. France Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
    • 5.5.13. U.K. Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 5.5.14. U.K. Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 5.5.15. U.K. Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 5.5.16. U.K. Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
    • 5.5.17. Spain Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 5.5.18. Spain Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 5.5.19. Spain Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 5.5.20. Spain Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
    • 5.5.21. Russia Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 5.5.22. Russia Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 5.5.23. Russia Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 5.5.24. Russia Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
    • 5.5.25. Rest of Europe Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 5.5.26. Rest of Europe Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 5.5.27. Rest of Europe Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 5.5.28. Rest of Europe Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
  • 5.6. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Geriatric Medicines Market Outlook, 2020-2033

  • 6.1. Asia Pacific Geriatric Medicines Market Outlook, by Therapeutic Area, Value (US$ Bn), 2020-2033
    • 6.1.1. Cardiovascular
    • 6.1.2. Central Nervous System
    • 6.1.3. Musculoskeletal
    • 6.1.4. Oncology
    • 6.1.5. Diabetes and Metabolic
    • 6.1.6. Respiratory
    • 6.1.7. Urological
    • 6.1.8. Ophthalmic
  • 6.2. Asia Pacific Geriatric Medicines Market Outlook, by Product Class, Value (US$ Bn), 2020-2033
    • 6.2.1. Generic Small Molecule
    • 6.2.2. Branded Small Molecule
    • 6.2.3. Biologic
    • 6.2.4. Biosimilar
  • 6.3. Asia Pacific Geriatric Medicines Market Outlook, by Formulation and Delivery Format, Value (US$ Bn), 2020-2033
    • 6.3.1. Conventional Oral Solid
    • 6.3.2. Orodispersible Tablet
    • 6.3.3. Liquid and Suspension
    • 6.3.4. Transdermal Patch
    • 6.3.5. Prefilled Device
    • 6.3.6. Fixed-Dose Combination
  • 6.4. Asia Pacific Geriatric Medicines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 6.4.1. Retail Pharmacy
    • 6.4.2. Hospital Pharmacy
    • 6.4.3. Long-Term Care Pharmacy
    • 6.4.4. Online Pharmacy
  • 6.5. Asia Pacific Geriatric Medicines Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.5.1. China Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 6.5.2. China Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 6.5.3. China Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 6.5.4. China Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
    • 6.5.5. Japan Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 6.5.6. Japan Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 6.5.7. Japan Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 6.5.8. Japan Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
    • 6.5.9. South Korea Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 6.5.10. South Korea Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 6.5.11. South Korea Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 6.5.12. South Korea Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
    • 6.5.13. India Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 6.5.14. India Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 6.5.15. India Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 6.5.16. India Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
    • 6.5.17. Southeast Asia Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 6.5.18. Southeast Asia Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 6.5.19. Southeast Asia Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 6.5.20. Southeast Asia Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
    • 6.5.21. Rest of SAO Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 6.5.22. Rest of SAO Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 6.5.23. Rest of SAO Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 6.5.24. Rest of SAO Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
  • 6.6. BPS Analysis/Market Attractiveness Analysis

7. Latin America Geriatric Medicines Market Outlook, 2020-2033

  • 7.1. Latin America Geriatric Medicines Market Outlook, by Therapeutic Area, Value (US$ Bn), 2020-2033
    • 7.1.1. Cardiovascular
    • 7.1.2. Central Nervous System
    • 7.1.3. Musculoskeletal
    • 7.1.4. Oncology
    • 7.1.5. Diabetes and Metabolic
    • 7.1.6. Respiratory
    • 7.1.7. Urological
    • 7.1.8. Ophthalmic
  • 7.2. Latin America Geriatric Medicines Market Outlook, by Product Class, Value (US$ Bn), 2020-2033
    • 7.2.1. Generic Small Molecule
    • 7.2.2. Branded Small Molecule
    • 7.2.3. Biologic
    • 7.2.4. Biosimilar
  • 7.3. Latin America Geriatric Medicines Market Outlook, by Formulation and Delivery Format, Value (US$ Bn), 2020-2033
    • 7.3.1. Conventional Oral Solid
    • 7.3.2. Orodispersible Tablet
    • 7.3.3. Liquid and Suspension
    • 7.3.4. Transdermal Patch
    • 7.3.5. Prefilled Device
    • 7.3.6. Fixed-Dose Combination
  • 7.4. Latin America Geriatric Medicines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 7.4.1. Retail Pharmacy
    • 7.4.2. Hospital Pharmacy
    • 7.4.3. Long-Term Care Pharmacy
    • 7.4.4. Online Pharmacy
  • 7.5. Latin America Geriatric Medicines Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.5.1. Brazil Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 7.5.2. Brazil Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 7.5.3. Brazil Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 7.5.4. Brazil Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
    • 7.5.5. Mexico Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 7.5.6. Mexico Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 7.5.7. Mexico Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 7.5.8. Mexico Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
    • 7.5.9. Argentina Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 7.5.10. Argentina Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 7.5.11. Argentina Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 7.5.12. Argentina Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
    • 7.5.13. Rest of LATAM Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 7.5.14. Rest of LATAM Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 7.5.15. Rest of LATAM Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 7.5.16. Rest of LATAM Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
  • 7.6. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Geriatric Medicines Market Outlook, 2020-2033

  • 8.1. Middle East & Africa Geriatric Medicines Market Outlook, by Therapeutic Area, Value (US$ Bn), 2020-2033
    • 8.1.1. Cardiovascular
    • 8.1.2. Central Nervous System
    • 8.1.3. Musculoskeletal
    • 8.1.4. Oncology
    • 8.1.5. Diabetes and Metabolic
    • 8.1.6. Respiratory
    • 8.1.7. Urological
    • 8.1.8. Ophthalmic
  • 8.2. Middle East & Africa Geriatric Medicines Market Outlook, by Product Class, Value (US$ Bn), 2020-2033
    • 8.2.1. Generic Small Molecule
    • 8.2.2. Branded Small Molecule
    • 8.2.3. Biologic
    • 8.2.4. Biosimilar
  • 8.3. Middle East & Africa Geriatric Medicines Market Outlook, by Formulation and Delivery Format, Value (US$ Bn), 2020-2033
    • 8.3.1. Conventional Oral Solid
    • 8.3.2. Orodispersible Tablet
    • 8.3.3. Liquid and Suspension
    • 8.3.4. Transdermal Patch
    • 8.3.5. Prefilled Device
    • 8.3.6. Fixed-Dose Combination
  • 8.4. Middle East & Africa Geriatric Medicines Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 8.4.1. Retail Pharmacy
    • 8.4.2. Hospital Pharmacy
    • 8.4.3. Long-Term Care Pharmacy
    • 8.4.4. Online Pharmacy
  • 8.5. Middle East & Africa Geriatric Medicines Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.5.1. GCC Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 8.5.2. GCC Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 8.5.3. GCC Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 8.5.4. GCC Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
    • 8.5.5. South Africa Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 8.5.6. South Africa Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 8.5.7. South Africa Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 8.5.8. South Africa Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
    • 8.5.9. Egypt Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 8.5.10. Egypt Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 8.5.11. Egypt Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 8.5.12. Egypt Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
    • 8.5.13. Nigeria Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 8.5.14. Nigeria Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 8.5.15. Nigeria Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 8.5.16. Nigeria Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
    • 8.5.17. Rest of Middle East Geriatric Medicines Market Outlook, by Therapeutic Area, 2020-2033
    • 8.5.18. Rest of Middle East Geriatric Medicines Market Outlook, by Product Class, 2020-2033
    • 8.5.19. Rest of Middle East Geriatric Medicines Market Outlook, by Formulation and Delivery Format, 2020-2033
    • 8.5.20. Rest of Middle East Geriatric Medicines Market Outlook, by Distribution Channel, 2020-2033
  • 8.6. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Pfizer Inc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Novartis AG
    • 9.4.3. Sanofi
    • 9.4.4. GSK plc
    • 9.4.5. AstraZeneca plc
    • 9.4.6. Bayer AG
    • 9.4.7. Eli Lilly and Company
    • 9.4.8. Novo Nordisk A/S
    • 9.4.9. Takeda Pharmaceutical Company Limited
    • 9.4.10. Boehringer Ingelheim International GmbH

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!